Residency · Residency · Otolaryngology

Unified Airway: Relationship Between Upper and Lower Airway Disease

Introduction

The unified airway model proposes that the upper and lower respiratory tracts function as a single, integrated unit sharing common respiratory epithelium, vascular supply, and immunologic responses. Inflammatory disease in one segment of the airway frequently affects the other, as exemplified by the strong association between allergic rhinitis, chronic rhinosinusitis, and asthma. This concept has profound implications for diagnosis and treatment in otolaryngology.

Anatomic and Histologic Basis

Continuous Respiratory Epithelium

The nasal cavity, paranasal sinuses, pharynx, larynx, trachea, and bronchi are lined by pseudostratified ciliated columnar epithelium. Common mucosal immune system (CMIS) means that sensitization at one site produces inflammation throughout the airway. Nasobronchial reflex: nasal irritation can trigger bronchospasm via vagal afferents.

Shared Inflammatory Mediators

Eosinophils: hallmark cells in both allergic rhinitis and asthma. Th2 cytokines (IL-4, IL-5, IL-13): drive IgE production and eosinophilic inflammation in both nose and lungs. Leukotrienes and prostaglandins: produced in both upper and lower airways. Epithelial barrier dysfunction: shared defect allowing allergen penetration.

Epidemiologic Evidence

80% of asthmatics have concomitant rhinitis. 20-40% of allergic rhinitis patients have asthma. Allergic rhinitis is an independent risk factor for developing asthma (OR 3-5). Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with asthma in 25-50% of cases. Aspirin-exacerbated respiratory disease (AERD/Samter triad): nasal polyposis, asthma, NSAID sensitivity — a paradigm of unified airway disease. Treatment of rhinitis has been shown to improve asthma outcomes.

Clinical Manifestations of Unified Airway Disease

Allergic Rhinitis and Asthma

Seasonal exacerbation of both nasal and bronchial symptoms. Allergen challenge in the nose induces bronchial hyperreactivity. Treating rhinitis with intranasal corticosteroids reduces asthma-related ER visits and hospitalizations.

Chronic Rhinosinusitis and Asthma

Shared Type 2 inflammatory endotype in CRSwNP and eosinophilic asthma. Severity of sinus disease correlates with asthma severity. Endoscopic sinus surgery in CRS patients improves asthma control and reduces oral steroid use.

AERD (Samter Triad)

Nasal polyposis + asthma + NSAID/aspirin hypersensitivity. Overproduction of cysteinyl leukotrienes (LTC4, LTD4, LTE4). Underproduction of prostaglandin E2 (anti-inflammatory). Management: aspirin desensitization, leukotriene modifiers, ESS, biologic therapy.

Pathophysiologic Mechanisms Linking Upper and Lower Airways

Postnasal Drip and Aspiration

Inflammatory mediators and mucus drain from the nose/sinuses into the lower airway. Direct transfer of eosinophils and cytokines to the bronchi.

Nasobronchial Reflex

Nasal irritation activates trigeminal afferents, triggering vagal-mediated bronchospasm. Demonstrated with nasal allergen challenge studies.

Systemic Inflammation

Nasal allergen challenge increases bone marrow production of eosinophils. Circulating inflammatory cells traffic to both upper and lower airway sites. This explains why treating the nose can improve the lungs and vice versa.

Oral Breathing

Nasal obstruction leads to mouth breathing, bypassing nasal filtration, humidification, and warming. Unfiltered, dry air reaches the lower airways, triggering bronchospasm.

Diagnostic Approach

Combined assessment: every patient with asthma should be evaluated for rhinitis/sinusitis and vice versa. Pulmonary function tests (PFTs): spirometry in CRS patients with asthma symptoms. CT sinuses: in asthmatics with refractory disease, nasal symptoms, or polyposis. Allergy testing: skin prick or serum-specific IgE for common aeroallergens. Nasal endoscopy: assess for polyps, mucosal edema, purulence.

Treatment Implications

Intranasal corticosteroids: reduce nasal and systemic inflammation; shown to decrease asthma exacerbations. Leukotriene receptor antagonists (montelukast): treat both nasal and bronchial symptoms; particularly useful in AERD. Immunotherapy: disease-modifying for both allergic rhinitis and allergic asthma. Biologics: dupilumab (anti-IL-4/IL-13), omalizumab (anti-IgE), mepolizumab (anti-IL-5) treat both CRSwNP and eosinophilic asthma simultaneously. Endoscopic sinus surgery: improves both sinus and asthma outcomes in well-selected patients. Aspirin desensitization: in AERD, reduces polyp recurrence and improves asthma control.

Key Clinical Pearls

Always ask about asthma symptoms in patients presenting with chronic rhinosinusitis, especially those with nasal polyps. Treatment of upper airway disease (allergic rhinitis, CRS) improves asthma control — reinforcing the unified airway concept. AERD is the prototypical unified airway disease; these patients require coordinated management of polyps, asthma, and NSAID sensitivity. Biologics targeting Type 2 inflammation represent a paradigm shift, treating both upper and lower airway disease simultaneously. Preoperative optimization of asthma is critical before any general anesthetic, especially for sinus surgery.

References

1. Grossman J. One airway, one disease. Chest. 1997;111(2 Suppl):11S-16S.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147-S334.
3. Hamilos DL. Chronic rhinosinusitis: epidemiology and medical management. J Allergy Clin Immunol. 2011;128(4):693-707.
4. Stevens WW, Peters AT, Hirsch AG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5(4):1061-1070.

Read this lecture as Markdown